Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California.

Details for the oral presentation related to seralutinib, an inhaled, PDGFR, CSF1R and c-KIT inhibitor, designed for the treatment of pulmonary hypertension, are as follows:

Session: A14: Building Lego(Land): Lessons Learned From Large Scale Clinical Trials In PAH Session Date & Time: Sunday, May 19th, 9:15 a.m. - 11:15 a.m. PT Talk Title: Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH) Location: San Diego Convention Center, Room 29A-D (Upper Level) Presenting Author: Olivier Sitbon, MD, PhD

Gossamer also will present additional data on seralutinib via poster. Details for those posters are as follows:

Poster Board Number: 424 Poster Session: D105 Balboa Park Explorers: Translational Science and Epidemiology in PH Session Date & Time: Wednesday, May 22nd, 11:00 a.m. – 1:00 p.m. PT Poster Title: TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve with Treatment Location: San Diego Convention Center, Room 25A-C (Upper Level)

Poster Board Number: 318 Poster Session: D109 Now We Got Bad Blood: RSF/PC Joint Session on Pulmonary Vascular Disease Session Date & Time: Wednesday, May 22nd, 11:00 a.m. – 1:00 p.m. PT Poster Title: Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates with Hemodynamics and Is Consistent with REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial Location: San Diego Convention Center, Room 28C-E (Upper Level)

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514616477/en/

For Investors and Media: Bryan Giraudo, Chief Operating Officer and Chief Financial Officer Gossamer Bio Investor Relations [e-mail]